Moffitt Cancer Center has gone live with its next-generation health and research informatics (HRI) platform, built on Oracle Health Sciences solutions. In early deployment, the new platform enables Moffitt to accelerate clinical trial patient recruitment and advance personalized medicine.
The new informatics environment, built using Oracle Health Sciences Enterprise Healthcare Analytics, Oracle Healthcare Master Person Index, Oracle Fusion Middleware, and Oracle Database 11g, supports Moffitt’s Total Cancer Care™ program by generating new intelligence from existing systems.
Securely synthesizing data from numerous clinical sources, a state-of-the-art biobank, and patient-reported information, the Oracle solution delivers rapid and accurate analysis that is helping to reveal new insight around treatment effectiveness at an individual level, with the goal of advancing personalized medicine initiatives.
Since deploying the solution, Moffitt has experienced an increase in the number of data requests from researchers and has streamlined patient cohort identification for cancer treatment studies.
“Oracle is honored to play a foundational role in Moffitt Cancer Center’s new health and research informatics platform,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. “Even in its early deployment, the platform shows tremendous potential to help Moffitt Cancer Center advance its personalized medicine initiative and improve outcomes. Moffitt’s work in this area is a testament to the power of IT to drive innovation in healthcare.”
Moffitt has automated clinical trial candidate identification, eliminating a manualeffort that required months of reviewing paper and electronic data sources to identify the best candidates. Today, researchers can access information on-demand, from their desktops to find de-identified patient cohorts withinminutes. Increasing the volume of data available for analysis will enable Moffitt to identify and validate targeted patient populations for cancer trials and, thereby, improve clinical trial efficiency and productivity.
Data collected electronically at the point-of-care can be made available for advanced research studies. Discoveries from this research will ultimately be reincorporated into clinical decision support tools that facilitate the delivery of individualized and personalized patient care.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.